Prot #PR-30-5020-C: A Phase 2, Open-Label, Single-Arm Study to Evaluate the Safety and Efficacy of Niraparib in Patients with Advanced, Relapsed, High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Who Have Received at Least

Project: Research project

Project Details

StatusFinished
Effective start/end date5/20/15 → 8/31/20

Funding

  • DrugDev Inc. (Prot #PR-30-5020-C // Prot #PR-30-5020-C)
  • TESARO, Inc. (Prot #PR-30-5020-C // Prot #PR-30-5020-C)